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Background: Extracorporeal photopheresis is an immunomodulatory
technique in which a patient’s leukocytes are exposed to ultraviolet-A
light after pretreatment with 8-methoxypsoralen (methoxsalen). There
have been few reports describing the use of extracorporeal photophere-
sis in lung transplant recipients. Methods: We reviewed our experience
using extracorporeal photopheresis in 8 lung transplant recipients since
1992. All 8 patients had progressively decreasing graft function and 7
were in bronchiolitis obliterans syndrome grade 3 before the initiation
of photopheresis. One patient had undergone a second transplant oper-
ation for obliterative bronchiolitis. Two patients had a pretransplanta-
tion diagnosis of chronic obstructive pulmonary disease, 1 a 1-anti-
trypsin deficiency, 1 cystic fibrosis, 1 bronchiectasis, 1 idiopathic
pulmonary fibrosis, and 2 primary pulmonary hypertension. Before
refractory rejection developed, all patients had been treated with 3-drug
immunosuppression and anti-T-cell therapy. The median time from
transplantation to the start of extracorporeal photopheresis was 16.5
months and the median number of treatments was 6. Results: The condi-
tion of 5 of 8 patients subjectively improved after extracorporeal photo-
pheresis therapy. In these 5 patients photopheresis was associated with
stabilization of the forced expiratory volume in 1 second. In 2 patients
there was histologic reversal of rejection after photopheresis. With a
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L ung transplantation is recognized as definitive ther-apy for patients with end-stage pulmonary failure.
However, long-term success with lung transplantation
has been limited by chronic rejection. Data from 2 cen-
ters have demonstrated that chronic rejection refractory
to medical therapy may develop in as many as 60% to
80% of lung transplant recipients.1 Current immuno-
suppressive strategies commonly involve a triple-drug
regimen for maintenance therapy and high-dose
steroids and/or antilymphocyte antibodies for rejection
episodes. Corticosteroid therapy is associated with sig-
nificant adverse effects that are related to the duration
of use and cumulative drug dose.2 Antilymphocytic
antibodies are limited by the production of anti-idio-
typic antibodies and are associated with the develop-
ment of viral infections and lymphoproliferative dis-
ease. Other treatments used for acute or refractory
rejection, such as methotrexate, have been associated
with an increased incidence of leukopenia and infec-
tious complications.2 The limitations of the currently
available immunosuppressive drugs underscore the
need for the development of other agents or techniques
for the treatment of allograft rejection.
Extracorporeal photopheresis (ECP) is a therapy that
produces a clone-specific antilymphocyte immune
response. ECP is performed by treating lymphocytes
obtained by leukapheresis, with 8-methoxypsoralen
(methoxsalen) followed by ultraviolet-A light (UVA)
exposure in an extracorporeal circuit. The treated
leukocytes are than reinfused to the patient, with the
apparent effect of down-regulating a specific immune
response. This therapy has been used for the treatment
of cutaneous T-cell lymphoma (CTCL), autoimmune
diseases, and allograft rejection. There are reports
detailing the efficacy of ECP for the treatment and pre-
vention of acute allograft rejection.2-10 Taken together,
these reports suggest that ECP is a safe, effective ther-
apy with only minimal side effects.
The literature contains only sporadic reports detailing
the use of ECP for the treatment of pulmonary allograft
rejection.11 At our institution ECP has been used as res-
cue therapy for patients with chronic rejection refracto-
ry to medical therapy. We performed this study to test
the hypothesis that ECP may arrest the decline of pul-
monary function and improve survival of lung trans-
plant recipients in bronchiolitis obliterans syndrome
(BOS) grade 3 with refractory rejection. Although all
patients were in BOS grade 3 at the initiation of ECP,
our review suggests that ECP may be associated with
increased survival and a preservation of pulmonary
function.
Patients and methods
Patients. Between 1992 and 1998, eight patients with
chronic refractory pulmonary graft rejection were treated
with ECP at the University of Minnesota (Table I). All
patients were having a progressive loss in pulmonary func-
tion and 7 were in BOS grade 3 at the initiation of ECP.
Patient 1 had undergone retransplantation for obliterative
bronchiolitis with no subsequent improvement in pulmonary
function. The median time from transplantation to the devel-
opment of BOS grade 3 in the ECP group was 12.8 months
(range 3-44 months). Seven patients underwent ECP as part
of an open label trial that was approved by the University of
Minnesota Human Subjects Committee. One patient was
treated with ECP before the initiation of the open label trial,
on a compassionate use basis with approval from University
of Minnesota Human Subjects Committee. During the same
time period, a concurrent, nonrandomized comparison group
was chosen from transplant recipients with BOS grade 3 who
were treated with medical therapy. The median time from
transplantation to the development of BOS grade 3 in the
comparison group was 27.2 months (range 6-68 months, log
rank c 2 = 1.86, P = .17 compared with the ECP group).
Clinical characteristics. Of the 8 patients, 3 were female
and 5 were male (Table I). Two patients had a pretransplanta-
tion diagnosis of chronic obstructive pulmonary disease
(COPD), 1 a 1-antitrypsin deficiency, 1 cystic fibrosis, 1
bronchiectasis, 1 idiopathic pulmonary fibrosis, and 2 prima-
ry pulmonary hypertension. The median age of the patients
was 43 years with a range of 13 to 60 years. Four patients had
undergone a single lung transplant and 4 had undergone bilat-
eral single lung transplants. The comparison group had simi-
lar demographics. Seven of the 20 patients were male. Five
patients had a pretransplantation diagnosis of COPD, 7 a 1-
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median follow-up of 36 months, 7 patients are alive and well. Three
patients required retransplantation at a median of 21 months after
completion of the treatments. Four patients have remained in stable
condition after photopheresis. There were no complications related to
extracorporeal photopheresis. Conclusion: We believe that this treatment
is a safe option for patients with refractory lung allograft rejection
when increased immunosuppression is contraindicated or ineffective. (J
Thorac Cardiovasc Surg 1999;117:1063-9)
antitrypsin deficiency, 1 Eisenmenger’s syndrome, and 1
lymphangiomyomatosis. The median age at transplantation
was 44 years with a range of 26 to 61 years. There were no
significant demographic differences between the 2 groups.
Immunosuppression. After transplantation, all patients
were maintained on a standard 3-drug immunosuppression
protocol consisting of cyclosporine (INN: ciclosporin) or
tacrolimus, azathioprine or mycophenolate mofetil, and pred-
nisone. Acute rejection episodes were treated with a steroid
bolus and taper. Rejection episodes refractory to glucocorti-
coid therapy were treated with anti-T-cell agents or
methotrexate. All 8 patients had previously received at least
one course of anti-T-cell therapy (antithymocyte globulin or
OKT3). Two patients were treated with methotrexate as res-
cue therapy.
ECP. PATIENT 1. The COBE Spectra (Cobe Laboratories,
Inc, Denver, Colo) primed with red blood cells and albumin
was used for the collection of mononuclear cells. Approxi-
mately 2 blood volumes (3500-4000 mL) were processed with
an average collection of 6.49 · 109 mononuclear cells. The
patient was given oral 8-methoxypsoralen 1.5 hours before the
procedure was begun. The mononuclear cells were exposed to
UVA light for 1.5 hours using the Therakos UVAR
Photopheresis System (Therakos, Inc, Exxon, Pa). After the
UVA exposure the mononuclear cells were reinfused.
PATIENTS 2 to 8. ECP was performed with the Therakos
UVAR Photopheresis System. During each photopheresis
treatment, approximately 300 mL of plasma and 240 mL of
buffy coat were separated and collected in 6 cycles of blood
collection. Subsequently 200 m g of liquid 8-methoxypso-
ralen, UVADEX (Therakos) was injected into the buffy coat.
The photoactivation of leukocyte-rich mixture occurred dur-
ing an exposure of 1.5 hours to UVA light. The mixture was
reinfused immediately after the procedure.
Clinical follow-up. All 8 patients were followed up in the
standard fashion for lung transplant recipients at the
University of Minnesota. At scheduled intervals pulmonary
function tests were performed. Bronchoscopic graft biopsy
specimens were taken on a scheduled basis and as dictated by
the clinical course. Medical records were reviewed as neces-
sary to complete the data set.
Statistical methods. Rates of change in forced expiratory
volume in 1 second (FEV1) were determined for each indi-
vidual subject for the period before ECP and the period after
the initiation of ECP by regressing their months after trans-
plantation on FEV1. Rates of change before ECP were deter-
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Table I. Clinical data
Time to 
Patient Primary Type of initiation No. of ECP 
(age, sex) illness transplant of ECP (mo) treatments Clinical outcome
1 (13, F) PPH Bilateral SLT 7 12 Clinically stable, reversal of biopsy-proven 
rejection
2 (60, M) COPD Left SLT 17 3 Retransplant 15 mo after treatment
3 (45, M) a 1 Right SLT 19 4 Retransplant 21 mo after treatment
4 (43, M) Bronchiectasis Bilateral SLT 12 6 Reversal of biopsy-proven rejection
5 (30, F) PPH Bilateral SLT 16 6 Clinically stable
6 (41, M) Cystic fibrosis Bilateral SLT 7 4 Died 18 mo after treatment
7 (57, F) COPD Right SLT 32 8 Retransplant 25 mo after treatment
8 (52, M) PPH Left SLT 42 13 Stable
ECP, extracorporeal photopheresis; PPH, primary pulmonary hypertension; COPD, chronic obstructive pulmonary disease; a 1, a 1-antitrypsin deficiency; SLT, sin-
gle lung transplantation.
Table II. Rates of change in FEV1 per month
Before ECP After ECP
Rate of No. of Rate of No. of 
Subject change 95% CI t P value data points change 95% CI t P value data points
1 .008 –.005, .022 1.3 .22 17 .006 .000, .012 2.2 .04 21
2 –.090 –.107, –.072 –11.3 <.001 13 –.03 –.061, –.002 –2.5 .04 9
3 –.116 –.148, –.084 –7.8 <.001 15 –.007 –.016, .003 –1.8 .12 8
4 –.117 –.19, –.043 –3.6 .006 11 .044 –.007, .094 2.05 .08 9
5 –.090 –.139, –.041 –4.8 .005 7 –.005 –.119, .109 –.57 .67 4
6 –.366 –.562, –.170 –4.6 .004 8 .0005 –.003, .004 .42 .7 5
7 –.014 –.018, –.011 –8.1 <.001 25 –.01 –.019, –.007 –5.6 .001 8
8 –.024 –.030, –.017 –7.8 <.001 19 .006 –.039, .051 .59 .62 4
FEV1, Forced expiratory volume in 1 second; ECP, extracorporeal photopheresis; CI, confidence interval.
mined from the date that the baseline FEV1 was set for each
subject according to the criteria established by the
International Society for Heart and Lung Transplantation
(ISHLT).1 Rates of change after ECP were determined from
the start date of ECP treatments. The assumption of linearity
was assessed by plotting the FEV1 against the months after
transplantation for each subject individually. No evidence
that associations were nonlinear was observed. The b -coeffi-
cients resulting from these regressions are the rate of change
in FEV1 per month, and the hypothesis that the b is zero was
tested for each subject’s rate of change at both time periods.
Because of the non-normal distribution of the rates of change,
a 1-sample Wilcoxon signed-rank test was performed to
assess whether the rate of change in FEV1 for pre-ECP and
post-ECP periods was significantly different from zero. A
Wilcoxon matched-pairs signed-rank test was used to deter-
mine whether there was a significant difference between rates
of change before to after ECP.12 To better illustrate the rate of
change in FEV1 across subjects before and after ECP, a pre-
sentation of each individual subject’s regression coefficients
(rate of change), 95% confidence intervals, t statistics, P val-
ues, and graphed regression lines are presented both before
and after ECP. Survival from the diagnosis of BOS grade 3
(or for patient 1 the initiation of ECP) was determined by
means of the Kaplan-Meier method, comparing the group that
received ECP with the comparison group. Differences in the
survival curves between groups were assessed by means of a
log-rank c 2 test. Statistical analysis was performed with the
use of SPSS (SPSS, Inc, Chicago, Ill) and SAS (SAS
Institute, Inc, Cary, NC) software.
Results
ECP treatments. The median time from transplanta-
tion to the initiation of ECP was 16.5 months (range 7-
42 months). The median number of treatments was 6
(range 3-13). There was no evidence of a decline in
leukocyte, platelet, or red blood cell count in any
patient after the initiation of ECP. No adverse effects
were reported from the ECP treatment, and no evidence
of an increase in opportunistic infections after ECP was
detected.
Pulmonary function tests. We examined the effect
of ECP on the rate of decline of FEV1. Fig 1 depicts
individual subject’s rate of decline in FEV1 before and
after ECP. In the ECP group, 7 of 8 patients had statis-
tically significant rates of decline in their FEV1 before
ECP. Five of these 7 patients had positive rates of
change or rates of change not significantly different
from zero after the initiation of ECP. Table I illustrates
the individual rates of change before and after ECP.
The median slope (B = –.09) in the pre-ECP period is
statistically different from zero (P = .02), whereas the
median slope (B = –.002) in the post-ECP period is not
significantly different from zero (P = 1.0). The differ-
ence in the rate of decline of FEV1 before and after
ECP is significant with a P value of .025.
Clinical efficacy. As depicted in Fig 2, ECP appears
to offer a trend toward improved survival when com-
pared with standard therapy. With a median follow-up
of 36.4 months (range 4-72), 7 of 8 patients (88%) in
the ECP group and 11 of 20 patients (45%) in the com-
parison group are alive. Four patients are in clinically
stable condition, and in 2 of these patients broncho-
scopic pulmonary biopsy specimens have demonstrat-
ed histologic reversal of a concurrent acute rejection
process associated with the onset of ECP. Three
patients have required retransplantation for progressive
pulmonary failure at 15, 21, and 25 months after ECP.
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Fig 1. Rates of decline in FEV1 before and after ECP. The
middle dot along each curve indicates the initiation of ECP.
Numbers at each line correspond to the subjects as listed in
Table I.
Fig 2. Kaplan-Meier survival curves comparing patients who
underwent ECP to a concurrent, nonrandomized comparison
group. Graph includes patients alive at selected points and
95% confidence intervals. Log-rank c 2 = 2.1; degrees of free-
dom = 1; P = .095.
All 3 patients are in clinically stable condition. One
patient died 18 months after ECP of progression of his
primary illness. In the comparison group, 3 of 20
patients have undergone retransplantation, and 1 of
these patients died in the early postoperative period.
Patients 1 and 4 had pulmonary biopsy specimens
that demonstrated reversal of an acute rejection episode
associated with ECP. Figs 3 and 4 are biopsy sections
from patient 4. The pre-ECP biopsy specimen demon-
strates chronic lymphocytic bronchitis and acute grade
2 rejection, and the post-ECP specimen demonstrates
improvement in the chronic lymphocytic bronchitis
and no evidence of acute rejection.
Discussion
ECP is an apheresis-based immunomodulatory ther-
apy that was first used clinically to treat CTCL. CTCL
is a lymphoid malignant disease characterized by the
expansion of a single lymphoid clone. After the report
by Edelson and associates13 that demonstrated ECP to
be highly efficacious for the treatment of CTCL, mul-
tiple groups have applied ECP to other diseases, which
are characterized by the expansion of a single T-cell
clone. ECP has been used successfully to treat pemphi-
gus vulgaris, rheumatoid arthritis, and allograft rejec-
tion. In general, ECP is very well tolerated, with only
sporadic reports of mild nausea, transient hypotension
associated with the apheresis, and rare low-grade fevers
after reinfusing the treated lymphocytes. Depletion of
the formed blood elements has not been noted.
The dominant mechanism of action by which ECP
modulates T cells remains to be identified. However,
multiple reports suggest that ECP acts via a variety of
mechanisms. First UVA light activates 8-methoxypso-
ralen (methoxsalen), leading to the cross-linking of
DNA and resulting in the inhibition of cell proliferation
and subsequent “photodestruction.”14 This represents
only a minor mode of action of ECP since only 2% to
5% of the entire white blood cell pool is affected with
each ECP treatment.14 Second, ECP has been shown to
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Fig 3. Pre-ECP transplant lung biopsy specimens from patient 4, demonstrating chronic lymphocytic bronchitis
and acute grade 2 rejection.
Fig 4. Post-ECP biopsy specimens from patient 4, demonstrating improved chronic lymphocytic bronchitis and
no evidence of rejection.
induce a nonspecific release of inflammatory mediators
(tumor necrosis factor-a , interleukin-1, and inter-
leukin-6), affecting the entire immune cell popula-
tion.15 Third, ECP induces apoptosis of peripheral
blood T-cell populations, which may play an important
immunomodulatory role.16 Last, most authors would
suggest that the primary mechanism of action is due to
the induction of a clone-specific suppressor T-cell
response.14-17 When ECP results in sublethal cellular
injury, a phenotypically altered cell is produced. The
altered cell actively immunizes the patient after reinfu-
sion of the treated cells.18
Multiple reports have been published demonstrating
the efficacy of ECP for the treatment or prophylaxis of
heart transplant rejection.2-10, 19-21 Rose and colleagues7
reported the successful use of ECP as adjuvant
immunotherapy in 4 heart transplant recipients with
elevated levels of panel-reactive antibodies. Meiser and
associates6 demonstrated that ECP as adjuvant
immunotherapy for heart transplant recipients signifi-
cantly decreased the number of acute rejection episodes
without increasing the number of infectious complica-
tions. Dall’Amico and colleagues4 used ECP in heart
transplant recipients with recurrent rejection. In this
study ECP reduced the number and severity of rejection
episodes and allowed a 44% reduction in the daily
immunosuppression therapy. Costanzo-Nordin and
coworkers2 reported a randomized study of 16 heart
transplant recipients in whom ECP was compared with
corticosteroid therapy. This study suggested that ECP
was as effective as corticosteroid therapy for the treat-
ment of heart transplant rejection and was associated
with no significant toxicity. Barr and associates10 com-
pared ECP with triple-drug immunosuppression to
triple-drug therapy alone in 23 heart transplant recipi-
ents. They did not identify a difference in the incidence
of acute rejection episodes or infections; however, the
ECP group demonstrated a trend toward a decreased
incidence of heart transplant atherosclerosis (20% vs
36%).
Far fewer reports have been published describing the
use of ECP for acute or chronic rejection in lung trans-
plant recipients. Andreau and coworkers11 reported a
case in which ECP was used to treat an acute episode
of lung rejection in a patient who had a severe infec-
tion. This patient had clinical improvement and histo-
logic reversal of the rejection episode. All other pub-
lished reports detailing the use of ECP for the treatment
of lung transplant rejection have been abstracts or let-
ters. O’Hagan and colleagues22 reported the use of ECP
in 4 lung transplant recipients with refractory oblitera-
tive bronchiolitis. In their series the decline in FEV1
was stabilized in 3 of 4 patients. Achkar and associ-
ates23 presented the use of ECP in 11 lung transplant
recipients with severe BOS. They reported improve-
ment or stabilization in 6 of 11 patients. Slovis, Loyd,
and King24 reported the use of ECP in 3 patients with
biopsy-confirmed obliterative bronchiolitis. Similar to
the other investigators, in their series 3 of 3 patients had
stabilization or improvement in pulmonary function.
Our results are consistent with those previously report-
ed. The condition of the majority of our patients
improved after the initiation of ECP. As a group, there
appeared to be enhanced survival, stabilization in the
decline in FEV1, and in 2 patients there was histologic
reversal of a concurrent acute rejection process. Three
patients were bridged to retransplantation, and in con-
trast to the comparison group all patients undergoing
retransplantation are alive and well. It is important to
note that in the present series ECP was used as rescue
therapy and that there was no increase in the rate of
infectious complications. Given the favorable results of
this review, we have begun to initiate ECP before the
development of BOS grade 3 and in any patient in whom
additional immunosuppression is contraindicated.
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Discussion
Dr Larry R. Kaiser (Philadelphia, Pa). Please describe
the characteristics of BOS grade 3. You showed what
appeared to be acute rejection. You are seeing a decline in
FEV1. How much of this is an obliterative bronchiolitis pic-
ture, and how much is a Fick problem?
Dr Salerno. BOS grade 3 is a clinical diagnosis that sug-
gests that the patients have lost 50% of their FEV1 since the
time of transplantation. We do not have biopsy data on every
patient before and after ECP to suggest that all of them have
evidence of obliterative bronchiolitis. However, all these
patients had had multiple episodes of acute rejection before
the initiation of therapy and documented declines in their pul-
monary function, in addition to their ability to do exercise
and perform activities of daily living.
Dr David J. Sugarbaker (Boston, Mass). There really are
not too many ways out of the box when you encounter this
chronic, severe rejection. What are some of the contraindica-
tions to this therapy, which patients would you determine are
not candidates, which ones would be treated by total body
irradiation, and how do you select patients for this?
Dr Salerno. The one thing that should be stressed is that
this therapy is essentially nontoxic. In most of the studies that
have been published, especially in heart transplant recipients,
there are no significant adverse effects from this treatment.
The one group in whom it may not work is patients who do
not have any evidence of a competent immune system, be-
cause a competent immune system is needed to react to the
autovaccine. I think the only patient who could not undergo
this therapy is one who could not undergo the withdrawal of
500 mL of blood—someone who is either volume limited for
the machine or who is too hemodynamically unstable to have
the procedure.
Dr Walter Klepetko (Vienna, Austria). Did the presence of
clinical infectious episodes influence your choice of whether
to offer the patient ECP?
Dr Salerno. No, it actually did not. Of interest, there was
no increased evidence of infectious complications after the
initiation of therapy, specifically cytomegalovirus. One of
these patients has been treated for cytomegalovirus for a year
and still has no increased evidence of infection. 
Dr Klepetko. Did you also offer ECP to patients who had
repeated episodes of chronic infection within the lung affected
by obliterative bronchiolitis before the initiation of therapy? 
Dr Salerno. Yes. 
Mr Peter Goldstraw (London, England). If ECP is so
good, why don’t you use it earlier? Why don’t you use it
before transplantation?
Dr Salerno. My hunch is that if this therapy was used ear-
lier, the decline of the pulmonary function would never have
gotten as far as it has. One of the problems with this technol-
ogy is that it is still not approved by the Food and Drug
Administration for this application, so there are some issues
with reimbursement and not many centers have the machine.
I agree with you that it probably should be used earlier. There
is some evidence in the heart transplant recipients that pro-
phylactic therapy inhibits evidence of chronic rejection in
those patients.
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